(P014) Predictors of Long-Term Survival for Localized Prostate Cancer Treated With High-Dose Intensity-Modulated Radiation Therapy (IMRT) Stratified by National Comprehensive Cancer Network (NCCN) 2015 Guidelines in a Community Hospital Setting
IMRT use in a community hospital is equally as efficacious and minimally toxic as it is in leading academic institutions. Age at diagnosis was the only significant predictor of survival, suggesting that cancer-specific mortality is minimal after IMRT in localized prostate cancer.
Anthony G. Ricco, Rachelle Lanciano, MD, Alexandra Hanlon, PhD; Sidney Kimmel Medical College, Thomas Jefferson University; Philadelphia CyberKnife; University of Pennsylvania
OBJECTIVES: The primary goal of this study is to determine prognostic factors associated with freedom from biochemical failure (FFBF) and survival for men with localized prostate cancer treated with intensity-modulated radiation therapy (IMRT) in a community hospital setting according to the new National Comprehensive Cancer Network (NCCN) 2015 risk stratification guidelines.
METHODS: A total of 228 consecutive men treated with IMRT for organ-confined prostate cancer at Delaware County Memorial Hospital from 2003-when the IMRT program began-to 2012 were reviewed in this institutional review board–approved retrospective study. Biochemical failure was assessed using the Phoenix Nadir +2 definition (a rise by ≥ 2 ng/mL above the nadir prostate-specific antigen level). Toxicity was assessed using the Radiation Therapy Oncology Group group criteria with modification.
RESULTS: Ten-year actuarial FFBF for the entire group was 83.18%. Ten-year actuarial FFBF, stratified by 2015 NCCN risk stratification, was 95.2% for very-low-risk, 96.3% for low-risk, 81.5% for intermediate-risk, and 75.4% for high-risk patients. Eight-year actuarial FFBF was 38.7% for the very-high-risk group. Multivariable analysis revealed that only the five NCCN risk groups were independent predictors of FFBF.
Ten-year actuarial survival for the entire group was 61.14%. Ten-year actuarial overall survival (OS), stratified by 2015 NCCN risk stratification, was 68.80% for very-low-risk, 81.47% for low-risk, 67.24% for intermediate-risk, 46.30% for high-risk, and 54.93% for very-high-risk men. Ten-year OS rates, stratified by age, were 75.92% for age ≤ 71.5 years and 55.19% for age > 71.5 years. Multivariable analysis revealed that only age was an independent significant factor for survival, with P = .0008.
CONCLUSIONS: IMRT use in a community hospital is equally as efficacious and minimally toxic as it is in leading academic institutions. Age at diagnosis was the only significant predictor of survival, suggesting that cancer-specific mortality is minimal after IMRT in localized prostate cancer.
Proceedings of the 98th Annual Meeting of the American Radium Society - americanradiumsociety.org
Frontline Chemo-Free Regimen Supported in HR+/HER2+ Breast Cancer Therapy
January 1st 2024Combining anastrozole with palbociclib, trastuzumab, and pertuzumab as a frontline therapy for hormone receptor–positive, HER2-positive breast cancer may avoid some of the toxicities associated with chemotherapy, says Amy Tiersten, MD.
Oncology On-The-Go Podcast: ASCO 2023 Recap
June 19th 2023Experts from University of California, Los Angeles Health and Mayo Clinic discuss key data presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting in the gynecologic and gastrointestinal cancer spaces and how they may impact patient care.
